Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma, liver and kidneys in streptozotocin-induced diabetic mice

Journal of Diabetes Investigation

Volumn 5, Issue 6, 2014, Pages 639-648

  Nojiri, Takahiro ^a   Kurano, Makoto ^b   Tokuhara, Yasunori ^a,c   Ohkubo, Shigeo ^a   Hara, Masumi ^d   Ikeda, Hitoshi ^a,b   Tsukamoto, Kazuhisa ^e   Yatomi, Yutaka ^a,b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apolipoprotein M; Sphingosine 1 phosphate; Streptozotocin induced diabetes mice

Indexed keywords

APOLIPOPROTEIN M; GLUCOSE; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN; SPHINGOSINE 1 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; HEPG2 CELL LINE; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN DETERMINATION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TISSUE LEVEL;

EID: 84911382893     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12232     Document Type: Article

References (25)

1. Johnson JD, Luciani DS. Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Adv Exp Med Biol 2010; 654: 447-462.
2. Marchetti P, Bugliani M, Boggi U, et al. The pancreatic beta cells in human type 2 diabetes. Adv Exp Med Biol 2012; 771: 288-309.
3. Cnop M, Welsh N, Jonas JC, et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54(Suppl 2): S97-S107.
4. Yatomi Y. Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr Pharm Des 2006; 12: 575-587.
5. Maceyka M, Harikumar KB, Milstien S, et al. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012; 22: 50-60.
6. Cantrell Stanford J, Morris AJ, Sunkara M, et al. Sphingosine 1-phosphate (S1P) regulates glucose-stimulated insulin secretion in pancreatic beta cells. J Biol Chem 2012; 287: 13457-13464.
7. Qi Y, Chen J, Lay A, et al. Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic beta-cell death in diet-induced obese mice. FASEB J 2013; 10: 4294-4304.
8. Jessup CF, Bonder CS, Pitson SM, et al. The sphingolipid rheostat: a potential target for improving pancreatic islet survival and function. Endocr Metab Immune Disord Drug Targets 2011; 11: 262-272.
9. Fox TE, Bewley MC, Unrath KA, et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res 2011; 52: 509-517.
10. Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011; 108: 9613-9618.
11. Xu N, Dahlback B. A novel human apolipoprotein (ApoM). J Biol Chem 1999; 274: 31286-31290.
12. Kurano M, Tsukamoto K, Ohkawa R, et al. Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoprotein M. Atherosclerosis 2013; 229: 102-109.
13. Xu N, Nilsson-Ehle P, Ahren B. Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: partial reversal by insulin. Biochem Biophys Res Commun 2006; 342: 1174-1177.
14. Zhang X, Jiang B, Luo G, et al. Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. Biochim Biophys Acta 2007; 1771: 879-882.
15. Lan T, Bi H, Xu S, et al. Determination of sphingosine kinase activity in biological samples by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2010; 24: 1075-1083.
16. Yatomi Y. Plasma sphingosine 1-phosphate metabolism and analysis. Biochim Biophys Acta 2008; 1780: 606-611.
17. Niu N, Zhu X, Liu Y, et al. Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (ApoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. Diabetes Metab Res Rev 2007; 23: 21-25.
18. Wu X, Niu N, Brismar K, et al. Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes. Clin Biochem 2009; 42: 17-21.
19. Zhou JW, Tsui SK, Ng MC, et al. Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. PLoS ONE 2011; 6: e17324.
20. Feingold KR, Shigenaga JK, Chui LG, et al. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008; 199: 19-26.
21. Zhang X, Zhu Z, Luo G, et al. Liver X receptor agonist downregulates hepatic ApoM expression in vivo and in vitro. Biochem Biophys Res Commun 2008; 371: 114-117.
22. Faber K, Axler O, Dahlback B, et al. Characterization of ApoM in normal and genetically modified mice. J Lipid Res 2004; 45: 1272-1278.
23. Zhang XY, Dong X, Zheng L, et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 2003; 105: 67-72.
24. Faber K, Hvidberg V, Moestrup SK, et al. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol 2006; 20: 212-218.
25. Koch A, Pfeilschifter J, Huwiler A. Sphingosine 1-phosphate in renal diseases. Cell Physiol Biochem 2013; 31: 745-760.